PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia

Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.1523
https://www.valueinhealthjournal.com/article/S1098-3015(12)03236-6/fulltext
Title : PRM60 General Methodological Issues in Cost-Effectiveness Analysis Inspired by the Assessment of Dasatinib, Nilotinib and Imatinib for 1st- Line Chronic Myeloid Leukaemia
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03236-6&doi=10.1016/j.jval.2012.08.1523
First page : A471
Section Title : Research on Methods
Open access? : No
Section Order : 1023
Categories :
Tags :
Regions :
ViH Article Tags :